AMGN vs REGN
AMGN and REGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | AMGNAmgen Inc. | REGNREGENERON PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $251.99B | — |
| P/E (TTM) | 29.0 | 20.5 |
| P/B | 21.56 | — |
| P/S | 6.9x | — |
| Dividend yield | 2.03% | — |
| Revenue | $38.09B(TTM) | $16.90B(TTM) |
| Revenue growth (YoY) | 10.0% | 1.0% |
| Net income | $8.74B(TTM) | $4.82B(TTM) |
| Earnings growth (YoY) | 88.5% | 2.1% |
| EPS, diluted | $16.10(TTM) | $45.24(TTM) |
| EBIT margin | 24.7% | 24.9% |
| ROE | 66.0% | 13.4% |
| ROIC | 15.1% | 9.2% |
| 1y total return | +62.9% | +41.7% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: AMGN vs REGN
| Metric | AMGN | REGN |
|---|---|---|
| End value | $42.1K | $26.9K |
| Total return | +320.8% | +169.3% |
| CAGR | +14.9% | +10.1% |
| Volatility | 25.1% | 32.3% |
| Sharpe | 0.51 | 0.33 |
| Sortino | 0.76 | 0.49 |
| Max drawdown | -24.9% | -59.7% |
Based on 2600 common trading days, 2016-06-29 → 2026-10-30 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)